Results 31 to 40 of about 208,281 (313)
MICAL redox enzymes and actin remodeling: New links to classical tumorigenic and cancer pathways
Molecular & Cellular Oncology, 2018 MICAL Redox enzymes have recently emerged as direct regulators of cell shape and motility – working through specific reversible post-translational oxidation of actin to disassemble and remodel the cytoskeleton.
Jimok Yoon, Jonathan R. Terman
doaj +1 more source
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein [PDF]
, 2013 Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen ...
Alessandro Pandini +11 more
core +1 more source
Journal for ImmunoTherapy of CancerBackground TIGIT was identified as a target immune checkpoint for overcoming resistance to PD-(L)1-blocking antibodies. However, the clinical efficacies of TIGIT antibodies were moderate in monotherapy and mixed in combination with PD-(L)1 antibodies.
Sang Hoon Lee +9 more
doaj +1 more source
Advanced Science, 2022 The Bcr/Abl plays a central role in Philadelphia chromosome‐positive (Ph+) leukemia because of the constitutively activated Abl tyrosine kinase and its downstream pathways.
Bohan Ma +8 more
doaj +1 more source
Abl Is Able to Inhibit Cell Engulfment
PLoS Biology, 2009 Programmed cell death is essential to development—it's how the tiny mitten of a growing hand becomes a glove of individuated fingers, for instance. To dispose of all those cellular corpses, nearby cells (or roving specialists such as the immune system's macrophages) engulf their dead neighbors and digest the remains.
openaire +5 more sources
İmatinib: Mechanisms of Action and Mechanisms of Resistance Development
Ankara Üniversitesi Tıp Fakültesi Mecmuas, 2012 İmatinib is a specific drug which was developed for the treatment of chronic myelogenous leukemia (KML) and is the pioneer drug in this area. İmatinib mesylate (Glivec) is a derivative of 2-phenylaminopyrimidine.
M. Merve Tuğlu, Mehmet Melli
doaj +1 more source
A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]
, 2015 Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core +1 more source
EnABLing Cathepsin-Driven Melanoma Metastasis
Molecular & Cellular Oncology, 2018 Metastatic melanoma remains incurable for many due to its aggressive nature. Secreted cathepsins promote metastasis by cleaving matrix and activating pro-invasive proteases.
Rakshamani Tripathi, Rina Plattner
doaj +1 more source
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells [PDF]
, 2008 Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including ...
Aulitzky, W. E. +6 more
core +1 more source
New perspectives on the roles of Abl tyrosine kinase in axon patterning
Fly, 2017 The Abelson tyrosine kinase (Abl) lies at the heart of one of the small set of ubiquitous, conserved signal transduction pathways that do much of the work of development and physiology.
Ramakrishnan Kannan, Edward Giniger
doaj +1 more source